Brian Schroer, MD, discusses key insights on eosinophilic esophagitis research

In this video, Brian Schroer, MD, allergist-immunologist at Cleveland Clinic, highlighted several key themes and research updates on eosinophilic esophagitis (EoE) presented at the recent American Academy of Allergy, Asthma & Immunology Annual Meeting.

A prominent topic of discussion was the fundamental origin of inflammation in EoE. Experts debated whether the esophageal epithelium inherently allows food allergens to penetrate and trigger inflammation, or the food allergens themselves cause the initial epithelial damage that subsequently leads to an allergic response.

Schroer also reviewed several significant studies from leading research institutions that are shaping the future of EoE management. A study from the Children's Hospital of Philadelphia explored the transcriptional signals of milk-specific T cells. Researchers identified specific markers on T cells that recognize milk epitopes, a discovery that could eventually be used to predict which patients are most likely to benefit from targeted milk-avoidance diets.

Another major focus at the conference was the pursuit of less invasive diagnostic and monitoring techniques. Currently, tracking EoE disease activity requires invasive procedures such as EGDs or transnasal endoscopies.

A study from the University of Cincinnati—a renowned center for EoE research—investigated peripheral blood markers as potential alternatives. Although inflammation-specific markers did not show a strong correlation, standard absolute counts for eosinophils, basophils, and neutrophils on routine blood tests were found to be moderately correlated with disease activity, offering hope for simpler, noninvasive monitoring in the future.

The discussion also heavily featured dupilumab, a highly effective biologic treatment for EoE. A longitudinal post hoc analysis demonstrated its sustained efficacy over 52 weeks, particularly in alleviating challenging symptoms such as odynophagia and dysphagia. However, a study out of Northwestern University revealed a critical nuance: Although dupilumab significantly reduced food-specific IgE levels, this reduction did not translate to actual clinical food tolerance, as most patients still experienced reactions during subsequent food challenges.

Furthermore, research from Arkansas analyzed dupilumab treatment failures, noting an 80% response rate—defined as eosinophil counts dropping below 15— alongside a 14% nonresponse rate. Unfortunately, investigators were unable to pinpoint any baseline demographic markers that could predict these nonresponders.

In closing, Schroer emphasized the persistent unmet needs within the EoE community. He stressed that although current therapies are excellent, there remains a critical demand for even better, more targeted treatments. Additionally, establishing reliable, noninvasive methods to diagnose and monitor EoE via peripheral blood tests remains the holy grail of patient care, setting the stage for future clinical research.

No relevant disclosures.

Reference

Eosinophilic esophagitis (EoE). American Academy of Allergy, Asthma & Immunology. Accessed March 3, 2026. https://www.aaaai.org/conditions-treatments/related-conditions/eosinophilic-esophagitis